USPTO serial 90574267
LATTICE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- IN, SUNG HYUN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LATTICE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Carrie L. Kiedrowski
Carrie L. Kiedrowski Jones Day250 VESEY STREETNEW YORK, NY 10281-1047UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Consulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and clinical scientific laboratory services for testing clinical specimens for the purpose of providing information for medical research, clinical trials, and pre-clinical investigations; clinical research in the fields of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; clinical research, namely, accessing and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; conducting drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses in the nature of medical research, and pharmaceutical development, in the fields of omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; medical research in the nature of disease diagnoses and treatment determination, selection, and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others | ACTIVE | — |
| 044 | Providing genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a website featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ambry Genetics Corporation
- Other trademarks owned by Ambry Genetics Corporation
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LATTICE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 25, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 25, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 15, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 13, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 13, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 13, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 26, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 24, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 24, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 24, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 23, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 28, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 28, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 23, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 8, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 25, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 25, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 25, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 25, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 25, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 9, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 5, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 4, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 4, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 7, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 6, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 11, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 15, 2021 | NWAP | NEW APPLICATION ENTERED | — |